Development Clinical Studies - investigation into the efficacy of Mirococept in renal transplantation

Lead Research Organisation: King's College London
Department Name: Immunology Infection and Inflam Diseases

Abstract

This study is designed to improve the immediate function of a kidney transplant and also to improve its longterm outcome. A novel molecule has been designed that binds to the cell membranes of the kidney and reduces the inflammatory response after transplantation. This should result in a shorter hospital stay for the patient and a reduced need for dialysis after transplantation. There is also good evidence that improving the initial function of a kidney can improve longterm fuction, thus improving the outcome for the patient. This would also increase the number of kidneys available for transplanation to those on the waiting list.

Technical Summary

We are seeking to define a therapeutic approach to the prevention of damage to the kidney during the period immediately after transplantation. This damage is linked to activation of the complement system which occurs through recognition of the grafted organ as ?non-self? as shown in a MRC funded programme of work. We have approached this problem firstly by engineering a recombinant form of a human complement regulatory molecule known to be present in the normal kidney and secondly by modifying this molecule so that it can be delivered to the graft by perfusion before transplantation and retained within the kidney during the period that damage is thought to occur. Preclinical and exploratory clinical studies have indicated that this approach is safe and has the potential to reduce the incidence of delayed graft function in renal transplantation. We are now seeking to conduct a larger-scale multi-centre Phase II study to investigate the clinical utility of the approach. This will at the same time validate therapeutic targets identified by animal work.

Publications

10 25 50
publication icon
Asgari E (2014) Control of innate immunological mechanisms as a route to drug minimization. in Current opinion in organ transplantation

publication icon
Farrar CA (2014) Mechanisms of rejection: role of complement. in Current opinion in organ transplantation

publication icon
Farrar CA (2013) The innate immune system and transplantation. in Cold Spring Harbor perspectives in medicine

publication icon
Karegli J (2017) Thrombalexins: Cell-Localized Inhibition of Thrombin and Its Effects in a Model of High-Risk Renal Transplantation. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

publication icon
Manook M (2017) Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

 
Description Technology Strategy Board Assessor Briefing for Healthcare
Geographic Reach National 
Policy Influence Type Participation in advisory committee
 
Description Investigation into the efficacy of Mirococept in renal transplantation
Amount £213,310 (GBP)
Funding ID G1001197 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start  
 
Description KCL funding
Amount £32,500 (GBP)
Organisation King's College London 
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 09/2017
 
Description Wellcome Trust Translational award
Amount £1,300,000 (GBP)
Funding ID 098300/Z/12/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2013 
End 01/2016
 
Title APT154 
Description Complement inhibitor, precursor to Mirococept 
Type Of Material Technology assay or reagent 
Year Produced 2010 
Provided To Others? Yes  
Impact Demonstration of cofactor activity towards complement Factor I in this fragment of CR1 
 
Title APT542 
Description Precursor reagent for Mirococept manufacture 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact N/A 
 
Title Mirococept 
Description Complement inhibitor 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact N/A 
 
Description 24hr Emergency unblinding service 
Organisation ESMS Global
Country United Kingdom 
Sector Private 
PI Contribution providing emergency unblinding service for research centres
Collaborator Contribution Emergency service
Impact Unblinding service in place
Start Year 2012
 
Description Comark Instruments 
Organisation Comark Instruments
Country United Kingdom 
Sector Private 
PI Contribution Freezer temperature monitoirng system
Collaborator Contribution Ensure the cold storage condition of the drug are maintained
Impact System in place
Start Year 2013
 
Description Cytectin structural studies 
Organisation University of Oxford
Department Sir William Dunn School of Pathology
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided Cytectin
Collaborator Contribution Oxford University provided data on its structural interaction with membranes.
Impact Publication May 2013 Cell Reports Cell Rep. 2013 May 30;3(5):1369-77. doi: 10.1016/j.celrep.2013.04.029. Epub 2013 May 9. Structural basis for recognition of the pore-forming toxin intermedilysin by human complement receptor CD59. Johnson S, Brooks NJ, Smith RA, Lea SM, Bubeck D. PMID: 23665225 [PubMed - in process] PMCID: PMC3675674
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation Addenbrooke's Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation King's College London
Department Institute of Liver Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation NHS Blood and Transplant (NHSBT)
Country United Kingdom 
Sector Public 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation University of Cambridge
Department Department of Pathology
Country United Kingdom 
Sector Academic/University 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description DMEC (AB, KW, AC, ASF, DC, NT) 
Organisation University of Oxford
Department Nuffield Department of Surgical Sciences Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Data Monitoring and Ethics Committee for the EMPIRIKAL Trial: Chair and members: independent clinicians, immunologists and statisticians.
Collaborator Contribution Review of unblinded data and give recommendation to TSC
Impact Committee in place
Start Year 2013
 
Description Drug distribution, storage and packaging PCI Pharma Services 
Organisation PCI Pharma Services
Country Global 
Sector Private 
PI Contribution Storage and distribution for clinical supplies - Supply of information on trial design, formulation and storage requirements
Collaborator Contribution Provision of cGMP storage facilities and arrangements for distribution to trial centres
Impact Storage and distribution plan in place
Start Year 2013
 
Description EMPIRIKAL Consortium 
Organisation British Transplantation Society (BTS)
Department Clinical Trials Network
Country United Kingdom 
Sector Academic/University 
PI Contribution We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.
Collaborator Contribution Planning of the protocol. Potential patient involvement.
Impact First investigator meeting held October 2012. Protocol modifications.
Start Year 2012
 
Description EMPIRIKAL Consortium 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution We have provided the underpinning science to the clinical trial (EMPIRIKAL) of a novel membrane associated complement regulator, have formulated the clinical protocol and have secured funding with the MRC DCS to enable the study.
Collaborator Contribution Planning of the protocol. Potential patient involvement.
Impact First investigator meeting held October 2012. Protocol modifications.
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Barts Health NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Cardiff and Vale University Health Board
Country United Kingdom 
Sector Public 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Hammersmith Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation King's College Hospital NHS Foundation Trust (NCH)
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Manchester Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Royal Free London NHS Foundation Trust
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation Royal Infirmary of Edinburgh
Country United Kingdom 
Sector Hospitals 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation St George's Healthcare NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description Empirikal Patient Recruiting Centres 
Organisation University Hospitals Coventry and Warwickshire NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution recruitment to Cohort 1 of the study completed (n=80).
Collaborator Contribution recruitment to Cohort 1 of the study completed (n=80).
Impact recruitment to Cohort 1 of the study completed (n=80).
Start Year 2012
 
Description FujiFilm Diosynth Biotechnologies 
Organisation Fujifilm
Department Fujifilm Diosynth Biotechnologies
Country United States 
Sector Private 
PI Contribution drug Substance manufacture - Provided update to manufacturing process, regular check on manufacturing step and QA/QC. Developed new assay for drug product
Collaborator Contribution Produced drug substance to cGMP with associated documentation and stability studies
Impact Drug substance suitable for clinical trial formulation
Start Year 2011
 
Description KCL CTU 
Organisation King's College London
Department King's Clinical Trials Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Provided Macros 4 trial eCRF database
Collaborator Contribution ensure the integrity of the data being collected
Impact Database in place
Start Year 2013
 
Description Mirococept collaboration with Cambridge University 
Organisation University of Cambridge
Department Veterinary School
Country United Kingdom 
Sector Academic/University 
PI Contribution Supplied Mirococept and other reagents and collaborated in experiments.
Collaborator Contribution Providing laboratory facilities and Factor I
Impact Supportive data for clinical use of Mirococept in novel indications.
Start Year 2013
 
Description Progeny 
Organisation Progeny Software inc
Country Canada 
Sector Private 
PI Contribution Provided the samples LIMS systems
Collaborator Contribution Enusre human tissue act is abided
Impact Database in place
Start Year 2013
 
Description Protein Therapeutics Laboratory 
Organisation King's College London
Department Protein Therapeutics Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution Will complete the analysis of particpant research samples
Collaborator Contribution Will complete the analysis of particpant research samples
Impact Samples analysis programme in place
Start Year 2010
 
Description Randomisation System 
Organisation Sealed Envelope
Country United Kingdom 
Sector Private 
PI Contribution produced randomisation kit numbers accordinly to the projet stratification factors
Collaborator Contribution Randomisation data base
Impact Randomisation data base in place
Start Year 2013
 
Description Trial Steering Committee 
Organisation Guy's and St Thomas' NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Collaborator Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Impact Committee in place
Start Year 2010
 
Description Trial Steering Committee 
Organisation King's College London
Department Division of Health and Social Care Research
Country United Kingdom 
Sector Academic/University 
PI Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Collaborator Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Impact Committee in place
Start Year 2010
 
Description Trial Steering Committee 
Organisation King's College London
Department MRC Centre for Transplantation
Country United Kingdom 
Sector Public 
PI Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Collaborator Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Impact Committee in place
Start Year 2010
 
Description Trial Steering Committee 
Organisation University of Oxford
Department Oxford Transplant Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Collaborator Contribution Provide guidance on the management and safety recommendation of the DMEC of the trial; representation on the steering Committee from project manager, statsician, patient, clinicians and immunologists
Impact Committee in place
Start Year 2010
 
Description Vialling Company Aesica 
Organisation Aesica Pharmaceuticals
Country United Kingdom 
Sector Private 
PI Contribution Drug product manufacture - Supply of drug specification and previous stability data
Collaborator Contribution Producedand stored vialled drug product as frozen solution fomulation performed sterility tests etc
Impact Drug Product suitable for clinical trials
Start Year 2012
 
Description Well Child Clinic Professor Neil Dalton 
Organisation King's College London
Department WellChild Laboratory
Country United Kingdom 
Sector Academic/University 
PI Contribution Will complete the analysis of participant research samples
Collaborator Contribution Will complete the analysis of participant research samples
Impact Samples analysis programe in place
Start Year 2010
 
Title Anticomplement Compounds 
Description Recovery of IP and materials related to membrane-localising ("cytotopic") technology discovered by our lead protein chemist and head of Protein Therapeutics Laboratory (before joining our Centre). 
IP Reference US7888318 
Protection Patent granted
Year Protection Granted 2011
Licensed Commercial In Confidence
Impact Return of the IP will enable new grant proposals and the conduct of a Phase IIB efficacy study in transplant patients.
 
Title Antithrombotic Compounds 
Description It has been found that linkage of anticoagulant peptides to membrane-localising ("cytotopic") reagents generates conjugates which are capable of inhibiting thrombin when attached to cell surfaces. This enables organs to be anticoagulated by perfusion ex-vivo prior to transplantation into the recipient. For the first time, it appears to be possible to separate local antithrombotic effects from systemic pharmacological ones using a readily translatable therapeutic agent. 
IP Reference WO2011027175 
Protection Patent granted
Year Protection Granted 2011
Licensed No
Impact It may be possible to control thrombosis in transplantation (for example, in pancreatic and islet cell transplantation and in the prevention of antibody-mediated acute rejection) using this approach, as shown in early pre-clinical models in rat.
 
Title Mirococept in renal transplantation 
Description The right to use Mirococept in a specific perfusion formulation for use in kidneys prior to transplantation is protected by a patent. The finding that Mirococept can provide protection to organs immediately following 
IP Reference WO2011027175 
Protection Patent granted
Year Protection Granted 2010
Licensed No
Impact Mirococept is being explored for several other indications
 
Title EMPIRIKAL Trial 
Description The medical product is a protein therapeutic which consists of a fragment of the complement regulator known as CR1 coupled to a membrane-binding tail. It is introduced into the donor kidney prior to transplantation. The study is to determine impact on delayed graft function (ischaemia-reperfusion injury). We completed recruitment of the 1st cohort of patients in 2016 and completed follow up in 2017. We will complete the data analysis by April 2018. There is an ongoing dosing/toxicity study in pig kidney, with a view to submitting a further clinical evaluation study proposal based on the pig study and cohort 1 data, expected submission 2019. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Refinement. Non-clinical
Year Development Stage Completed 2018
Development Status Under active development/distribution
Clinical Trial? Yes
Impact A second therapeutic agent (anti thrombin) using the same targeting modality for use in kidneys transplanted into highly sensitized recipients is being prepared for clinical evaluation, based on the knowledge and skills derived from the above study. 
URL http://www.isrctn.com/ISRCTN49958194
 
Title Empirikal-Mirococept 
Description Membrane - interactive complement inhibitor used by ex vivo perfusion into isolated organ. About to enter definitive Phase II study. Drug manufacture completed to accepted standard. MHRA approved. Patient recruitment imminent. Souce of funding: MRC DCS grant. Recruitment began in July 2015 and 19 patients are now undergoing treatment. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2006
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Validation of the membrane-binding (cytotopic) approach used in Mirococept and the consequent development of this technology as a platform. Large scale manufacture and quality assessment for clinical trial completed. Completed investigators brochure. Ethics approved. MHRA approved. Patient recruitment open. 
URL http://www.mykidney.org/Research/ResearchAtGuys.aspx
 
Description Complement UK training meeting - Complement for practitioners 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Training in Complement including mechanisms, bio markers and therapeutics, for medical practitioners and clinical laboratory scientists and industry.
Year(s) Of Engagement Activity 2017
 
Description EMPIRIKAL investigator meeting BTS Harrogate 2017 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presented baseline data and characteristics of Cohort 1 to other PI and Investigators. Generated discussion and questions between Investigators and will hopefully lead to other centres taking part in the next Cohort.
Year(s) Of Engagement Activity 2017
 
Description International conferenc on complement therapeutics Rhodes 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker at the 9th International conference on complement therapeutics, Rhodes 2016. Talk give on the Role of Collectin 11 in injury of the newly transplanted kidney providing opportunity for feedback and discussion
Year(s) Of Engagement Activity 2016
 
Description MRC Centenary- The Science and Art of Transplantation 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The exhibition, attended by 189 visitors throughout the day, consisted of five multimedia galleries, with volunteers from the Centre on hand throughout the day to speak to visitors about their research. • Pioneers Gallery - interviews from pioneers of science and transplantation, connecting MRC discoveries with the treatment of transplant patients today
• Extending the life of the transplant; "Pepper's Ghost" holographic model with kidney perfusion video footage
• A life without medication; multi-player video game
• Cell Transplantation; plasma information screen focusing on the hepatocyte programme, islet, and bone marrow work
• Patient journey; patient wall with stories from 28 transplant recipients and their families. Patients Richard Lane and Lesley Beadle also attended giving visitors the opportunity to hear first-hand about life as a transplant donor or recipient

84 % of those who returned a feedback form reported that the exhibition had improved their understanding of the Medical Research Council and of the work that it has achieved. Further, 81% claimed a better understanding of organ transplantation following the event.
• "Excellent exhibition. Great use of multimedia and very worthwhile exhibit. A very good way to commemorate the MRC!"
• "It was great! And no jargon so easily understandable"
• "Really enjoyed the exhibition and speaking with the researchers especially. The work they are doing is so interesting!"
• "Keep up the good work!"
• "I appreciated how well the professor explained the research and how encouraging they were"
• "Really enjoyed layout and presentation of projected images. Great interactive game!"

See text above for statistics and feedback. We have been asked to re-use some of our exhibits (the digital multiplayer interactive game showing transplant tolerance versus rejection) for the Science Museum late series for the MRC Max Perutz Science Writing Award ceremony.
Year(s) Of Engagement Activity 2013
URL http://transplantation.kcl.ac.uk/sections/site/education-information
 
Description MRC Centre 10th anniversary 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact The event consisted of artifacts, art, patient stories, wax models and a professional drama production (The Messenger) reflecting different aspects of our research, patient benefits and ethical issues of organ donation. It included prize presentations following the MRC Festival winners early in the year and for the best scientific images.
Year(s) Of Engagement Activity 2017
 
Description MRC Festival, Social Mobility Foundation visit to the MRC Centre 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Potential career seekers in Science visited for a 1 day program about the evolution of clinical trials from bench to bedside entitled "The life cycle of a clinical trial". They met with investigators involved in this work. With coaching from a professional illustrator they created their own art pieces and flow charts depicting the life cycle.
Year(s) Of Engagement Activity 2017
 
Description Seminar - Sir William Dunn School of Pathology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Interest and further discussions followed

Strengthened links in support of application for UKRMP Immunology Stem Cell Hub
Year(s) Of Engagement Activity 2014
 
Description Session Organiser for BSI 2013 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact None as yet - Meeting occurring 2-5 December 2013
Year(s) Of Engagement Activity 2013
URL http://www.bsicongress.com/
 
Description Speaker at BTS Glasgow conference, 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented Reseach to academic audience at the 2016 British Transplantation Society conference in Glasgow
Year(s) Of Engagement Activity 2016
 
Description Steve Sacks - 8th International Conference on Complement Therapeutics, Crete, Greece 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker
Year(s) Of Engagement Activity 2015
 
Description Steve Sacks - American Society of Nephrology, San Diego, USA 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker
Year(s) Of Engagement Activity 2015
 
Description Steve Sacks - BANFF-CST 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker for the BANFF-CST Joint Scientific Meeting, Vancouver, Canada
Year(s) Of Engagement Activity 2015
 
Description Steve Sacks - CEOT Symposium, Phoenix, USA 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker
Year(s) Of Engagement Activity 2016
 
Description Steve Sacks - Complement UK Symposium and Training Course, Cambridge, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Co-organiser and speaker
Year(s) Of Engagement Activity 2015
 
Description Steve Sacks - Joint British Transplantation Society and Nederlandse Tranplantatie Vereniging Congress, Bournemouth, UK 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker.
Talk title: ' A new signal for cell death in post-ischaemic injury'
Year(s) Of Engagement Activity 2015
 
Description Steve Sacks - Royal Society 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker, Royal Society Meeting on Complement: driver of inflammation and therapeutic target in diverse disease, Buckinghamshire, UK
Year(s) Of Engagement Activity 2015
 
Description clinical trials day 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Leaflet and attendance at clinical trials day organised by the GSTT NHS trust in hospital foyer - describing trials based within the centre - stall open to general public.
Year(s) Of Engagement Activity 2016